Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis ...

It is given as a subcutaneous injection (under the skin) once weekly. Learn more about where the best place to inject Zepbound is and what a typical dosing schedule looks like for the drug.

Roche Holdings AG's RHHBY Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...

The FDA approved ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo; Genentech), a twice-yearly subcutaneous injection, for relapsing multiple sclerosis (RMS) and primary progressive multiple ...

argenx SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, Vyvgart's 1000 mg dose, administered through a subcutaneous ...

The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.The agent (Tecentriq Hybreza, Genentech) is the first subcutaneous anti-PD-L1 cancer immunotherapy approved in the ...

The Food and Drug Administration (FDA) approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), a subcutaneous injection, for all previously approved indications of the intravenous ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase ...

If approved, Brixadi would be supplied as weekly (8mg, 16mg, 24mg, 32mg) and monthly (64mg, 96mg, 128mg) injections for subcutaneous use and would be used as part of a complete treatment plan to ...

The subcutaneous drug utilizes Halozyme's Enhanze drug delivery platform after Roche licensed the tech for $25 million—plus up to $165 million in milestones—back in 2018.

The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is indicated, according to a press release.Nivolumab and ...